Figure 3.

Cost differences are observed after the return of arrhythmia, breast cancer, and cardiomyopathy genomic results

Difference in spending after return of results minus before return for individuals receiving P/LP findings (blue) and negative (black) findings. There were significantly higher costs in three conditions (arrhythmia, p < 0.0001; breast cancer, p = 0.0013; and cardiomyopathy, p = 0.001), and a marginally significant difference in colorectal cancer (p = 0.059). No significant difference was observed in FH (p > 0.05). Box represents interquartile range (IQR), with whiskers representing variability outside the quartiles, and outliers represented as dots. Data shown are limited to 5 to 95 percentiles of costs. IQR for colorectal cancer and FH are 0. FH, familial hypercholesterolemia; ^∗p < 0.05.